Clinical Cancer Research, Vol 3, Issue 11 2121-2128, Copyright © 1997 by American Association for Cancer Research

ARTICLES

P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer

DF Jarrard, R Paul, A van Bokhoven, SH Nguyen, GS Bova, MJ Wheelock, KR Johnson, J Schalken, M Bussemakers and WB Isaacs
Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.

P-Cadherin is a member of the cadherin family of cell surface glycoproteins that mediate Ca2+-dependent cell-cell adhesion and is expressed in a differential fashion in normal epithelial tissues. The expression of P-cadherin in human prostate cancer development has not been investigated previously. By immunohistochemistry, we show that P-cadherin expression is restricted to the cell-cell border of basal epithelial cells in 30 normal prostate samples. This staining is down-regulated in prostatic intraepithelial neoplasia and is absent in all 25 of the well to poorly differentiated prostate cancer specimens analyzed. To examine potential P-cadherin-regulatory elements, we sequenced the 5'-flanking region of this gene. Similar to the mouse gene, the human P-cadherin promoter is TATA-less, contains an Sp-1 binding site and, analogous to the human E-cadherin sequence, demonstrates a GC-rich region characteristic of a CpG island. Cytosine methylation of this region occurs in P-cadherin-negative prostate cancer cell lines but not in cell lines expressing this gene. In vivo, a lack of expression in 12 clinical prostate cancer specimens is not associated with methylation of the P-cadherin promoter. These results demonstrate that the expression of the basal cell marker P-cadherin is lost in prostate cancer development and that in vivo mechanisms other than cytosine methylation regulate this consistent loss of expression.

This article has been cited by other articles:

				K. Gravdal, O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7003 - 7011. [Abstract] [Full Text] [PDF]

				J. Paredes, A. Albergaria, J. T. Oliveira, C. Jeronimo, F. Milanezi, and F. C. Schmitt P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation Clin. Cancer Res., August 15, 2005; 11(16): 5869 - 5877. [Abstract] [Full Text] [PDF]

				D. R. Hodge, B. Peng, J. C. Cherry, E. M. Hurt, S. D. Fox, J. A. Kelley, D. J. Munroe, and W. L. Farrar Interleukin 6 Supports the Maintenance of p53 Tumor Suppressor Gene Promoter Methylation Cancer Res., June 1, 2005; 65(11): 4673 - 4682. [Abstract] [Full Text] [PDF]

				J. Paredes, C. Stove, V. Stove, F. Milanezi, V. Van Marck, L. Derycke, M. Mareel, M. Bracke, and F. Schmitt P-Cadherin Is Up-Regulated by the Antiestrogen ICI 182,780 and Promotes Invasion of Human Breast Cancer Cells Cancer Res., November 15, 2004; 64(22): 8309 - 8317. [Abstract] [Full Text] [PDF]

				R. Govindarajan, S. Zhao, X.-H. Song, R.-J. Guo, M. Wheelock, K. R. Johnson, and P. P. Mehta Impaired Trafficking of Connexins in Androgen-independent Human Prostate Cancer Cell Lines and Its Mitigation by alpha -Catenin J. Biol. Chem., December 13, 2002; 277(51): 50087 - 50097. [Abstract] [Full Text] [PDF]